Trial Profile
A Phase II, Open Label, Non Randomised, Non Comparative, Multicentre Study to Assess the Efficacy and Safety of Olaparib Given Orally Twice Daily in Patients With Advanced Cancers Who Have a Confirmed Genetic BRCA 1 and/or BRCA2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 30 Jun 2023.
- 20 Feb 2022 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 22 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.